Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling–targeted agent in extending imaging-based progression-free survival, overall survival, and PSA...
Saved in:
| Published in | The New England journal of medicine Vol. 381; no. 26; pp. 2506 - 2518 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Massachusetts Medical Society
26.12.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling–targeted agent in extending imaging-based progression-free survival, overall survival, and PSA response. |
|---|---|
| AbstractList | BackgroundThe efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.MethodsWe randomly assigned, in a 1:1 ratio, patients who had previously received docetaxel and an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signaling–targeted inhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily). The primary end point was imaging-based progression-free survival. Secondary end points of survival, response, and safety were assessed.ResultsA total of 255 patients underwent randomization. After a median follow-up of 9.2 months, imaging-based progression or death was reported in 95 of 129 patients (73.6%) in the cabazitaxel group, as compared with 101 of 126 patients (80.2%) in the group that received an androgen-signaling–targeted inhibitor (hazard ratio, 0.54; 95% confidence interval [CI], 0.40 to 0.73; P<0.001). The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling–targeted inhibitor. The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling–targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P=0.008). The median progression-free survival was 4.4 months with cabazitaxel and 2.7 months with an androgen-signaling–targeted inhibitor (hazard ratio for progression or death, 0.52; 95% CI, 0.40 to 0.68; P<0.001), a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001), and tumor response was noted in 36.5% and 11.5% (P=0.004). Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling–targeted inhibitor. No new safety signals were observed.ConclusionsCabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling–targeted agent (abiraterone or enzalutamide). (Funded by Sanofi; CARD ClinicalTrials.gov number, NCT02485691.) The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear. We randomly assigned, in a 1:1 ratio, patients who had previously received docetaxel and an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signaling-targeted inhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily). The primary end point was imaging-based progression-free survival. Secondary end points of survival, response, and safety were assessed. A total of 255 patients underwent randomization. After a median follow-up of 9.2 months, imaging-based progression or death was reported in 95 of 129 patients (73.6%) in the cabazitaxel group, as compared with 101 of 126 patients (80.2%) in the group that received an androgen-signaling-targeted inhibitor (hazard ratio, 0.54; 95% confidence interval [CI], 0.40 to 0.73; P<0.001). The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor. The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008). The median progression-free survival was 4.4 months with cabazitaxel and 2.7 months with an androgen-signaling-targeted inhibitor (hazard ratio for progression or death, 0.52; 95% CI, 0.40 to 0.68; P<0.001), a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001), and tumor response was noted in 36.5% and 11.5% (P = 0.004). Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor. No new safety signals were observed. Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone or enzalutamide). (Funded by Sanofi; CARD ClinicalTrials.gov number, NCT02485691.). A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling–targeted agent in extending imaging-based progression-free survival, overall survival, and PSA response. The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.BACKGROUNDThe efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.We randomly assigned, in a 1:1 ratio, patients who had previously received docetaxel and an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signaling-targeted inhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily). The primary end point was imaging-based progression-free survival. Secondary end points of survival, response, and safety were assessed.METHODSWe randomly assigned, in a 1:1 ratio, patients who had previously received docetaxel and an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signaling-targeted inhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily). The primary end point was imaging-based progression-free survival. Secondary end points of survival, response, and safety were assessed.A total of 255 patients underwent randomization. After a median follow-up of 9.2 months, imaging-based progression or death was reported in 95 of 129 patients (73.6%) in the cabazitaxel group, as compared with 101 of 126 patients (80.2%) in the group that received an androgen-signaling-targeted inhibitor (hazard ratio, 0.54; 95% confidence interval [CI], 0.40 to 0.73; P<0.001). The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor. The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008). The median progression-free survival was 4.4 months with cabazitaxel and 2.7 months with an androgen-signaling-targeted inhibitor (hazard ratio for progression or death, 0.52; 95% CI, 0.40 to 0.68; P<0.001), a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001), and tumor response was noted in 36.5% and 11.5% (P = 0.004). Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor. No new safety signals were observed.RESULTSA total of 255 patients underwent randomization. After a median follow-up of 9.2 months, imaging-based progression or death was reported in 95 of 129 patients (73.6%) in the cabazitaxel group, as compared with 101 of 126 patients (80.2%) in the group that received an androgen-signaling-targeted inhibitor (hazard ratio, 0.54; 95% confidence interval [CI], 0.40 to 0.73; P<0.001). The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor. The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008). The median progression-free survival was 4.4 months with cabazitaxel and 2.7 months with an androgen-signaling-targeted inhibitor (hazard ratio for progression or death, 0.52; 95% CI, 0.40 to 0.68; P<0.001), a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001), and tumor response was noted in 36.5% and 11.5% (P = 0.004). Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor. No new safety signals were observed.Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone or enzalutamide). (Funded by Sanofi; CARD ClinicalTrials.gov number, NCT02485691.).CONCLUSIONSCabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone or enzalutamide). (Funded by Sanofi; CARD ClinicalTrials.gov number, NCT02485691.). |
| Author | Feyerabend, Susan Iacovelli, Roberto Sverrisdóttir, Ásgerður de Wit, Ronald Ozatilgan, Ayse Fizazi, Karim Melichar, Bohuslav Castellano, Daniel de Bono, Johann Bamias, Aristotelis Tombal, Bertrand Eymard, Jean-Christophe Helissey, Carole Theodore, Christine Sternberg, Cora N Carles, Joan Geffriaud-Ricouard, Christine Wülfing, Christian Kramer, Gero |
| Author_xml | – sequence: 1 givenname: Ronald surname: de Wit fullname: de Wit, Ronald organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 2 givenname: Johann surname: de Bono fullname: de Bono, Johann organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 3 givenname: Cora N surname: Sternberg fullname: Sternberg, Cora N organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 4 givenname: Karim surname: Fizazi fullname: Fizazi, Karim organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 5 givenname: Bertrand surname: Tombal fullname: Tombal, Bertrand organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 6 givenname: Christian surname: Wülfing fullname: Wülfing, Christian organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 7 givenname: Gero surname: Kramer fullname: Kramer, Gero organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 8 givenname: Jean-Christophe surname: Eymard fullname: Eymard, Jean-Christophe organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 9 givenname: Aristotelis surname: Bamias fullname: Bamias, Aristotelis organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 10 givenname: Joan surname: Carles fullname: Carles, Joan organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 11 givenname: Roberto surname: Iacovelli fullname: Iacovelli, Roberto organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 12 givenname: Bohuslav surname: Melichar fullname: Melichar, Bohuslav organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 13 givenname: Ásgerður surname: Sverrisdóttir fullname: Sverrisdóttir, Ásgerður organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 14 givenname: Christine surname: Theodore fullname: Theodore, Christine organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 15 givenname: Susan surname: Feyerabend fullname: Feyerabend, Susan organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 16 givenname: Carole surname: Helissey fullname: Helissey, Carole organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 17 givenname: Ayse surname: Ozatilgan fullname: Ozatilgan, Ayse organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 18 givenname: Christine surname: Geffriaud-Ricouard fullname: Geffriaud-Ricouard, Christine organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) – sequence: 19 givenname: Daniel surname: Castellano fullname: Castellano, Daniel organization: From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne–Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d’Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) — all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) — both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome — both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31566937$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10UlLxDAUAOAgio7L0asURPBSzdZMc5Rh3BiXg_fymr5ChjbVJBX115thVFAwl7zD95K37JJNNzgk5JDRM0YLdX4_v70bgGnGOFUbZMIKIXIpqdokE0p5mcupFjtkN4QlTYdJvU12BCuU0mI6IYsZ1PBhI7xhl72iD2PILmrrIaJPH2WDz-buA7oxQm8bzKzL7jBCiBCtyR79sIowm4Ez6PfJVgtdwIOve488Xc6fZtf54uHqZnaxyI0sVMybAow2yGspURhoyxI1U6LV3DBZ1pRLLVKApp3KljJKVd0A441OpYqaij1yun722Q8vI4ZY9TYY7DpwOIyh4lxrWUyVEIke_6HLYfQuFVdxIajisihX6uhLjXWPTfXsbQ_-vfoeUwL5GpjUcPDY_hBGq9Uaql9rSF788cauJja46MF2_2adrLP6PlQOl_0_7hM6QZVk |
| CitedBy_id | crossref_primary_10_1177_15579883221115593 crossref_primary_10_1038_s41416_021_01508_5 crossref_primary_10_1007_s40487_021_00160_6 crossref_primary_10_1136_jitc_2020_002022 crossref_primary_10_2217_fon_2021_0886 crossref_primary_10_1001_jamaoncol_2023_4255 crossref_primary_10_3390_cancers12040995 crossref_primary_10_1038_s41585_019_0270_7 crossref_primary_10_1038_s41585_020_0289_9 crossref_primary_10_1200_JCO_22_01726 crossref_primary_10_3390_cancers15133308 crossref_primary_10_3389_fimmu_2023_1265751 crossref_primary_10_3390_ijms241512508 crossref_primary_10_2967_jnumed_124_267922 crossref_primary_10_1080_14796694_2024_2442900 crossref_primary_10_1016_S0140_6736_24_01919_6 crossref_primary_10_1016_S1470_2045_22_00278_9 crossref_primary_10_3390_cancers12082148 crossref_primary_10_1016_j_urology_2022_12_025 crossref_primary_10_1016_j_urology_2022_12_026 crossref_primary_10_2217_pgs_2022_0023 crossref_primary_10_1002_cam4_4172 crossref_primary_10_1186_s13062_024_00500_2 crossref_primary_10_1016_j_clgc_2020_12_009 crossref_primary_10_1016_j_clgc_2020_12_008 crossref_primary_10_1038_s41391_020_0215_5 crossref_primary_10_1002_pros_24889 crossref_primary_10_1177_1758835920978134 crossref_primary_10_3389_fonc_2021_656146 crossref_primary_10_1016_j_clgc_2023_11_002 crossref_primary_10_1016_j_purol_2022_07_147 crossref_primary_10_3389_fphar_2023_1290990 crossref_primary_10_1016_j_clgc_2023_02_006 crossref_primary_10_1038_s41467_023_44514_2 crossref_primary_10_1016_j_eururo_2021_04_005 crossref_primary_10_2967_jnumed_121_262890 crossref_primary_10_21518_2079_701X_2020_20_90_99 crossref_primary_10_1016_j_euo_2020_05_006 crossref_primary_10_1055_a_1181_5912 crossref_primary_10_1016_j_euf_2020_05_018 crossref_primary_10_2967_jnumed_121_262413 crossref_primary_10_1158_1078_0432_CCR_21_2326 crossref_primary_10_3390_biomedicines9060661 crossref_primary_10_3390_biomedicines9091247 crossref_primary_10_1111_iju_15097 crossref_primary_10_1186_s13046_022_02406_1 crossref_primary_10_21518_2079_701X_2020_20_100_108 crossref_primary_10_1080_14656566_2021_1912015 crossref_primary_10_1097_MOU_0000000000001234 crossref_primary_10_3390_jcm9103346 crossref_primary_10_1016_j_critrevonc_2025_104678 crossref_primary_10_1080_14737140_2025_2481141 crossref_primary_10_2967_jnumed_124_267816 crossref_primary_10_1002_cncr_35612 crossref_primary_10_1158_2767_9764_CRC_23_0175 crossref_primary_10_1002_pros_24880 crossref_primary_10_2967_jnumed_121_262543 crossref_primary_10_1016_j_drup_2022_100865 crossref_primary_10_1111_ajco_13580 crossref_primary_10_1038_s41585_024_00902_x crossref_primary_10_1016_j_clgc_2024_102230 crossref_primary_10_29337_ijsonco_126 crossref_primary_10_3389_fonc_2021_655355 crossref_primary_10_1111_bju_16106 crossref_primary_10_1200_PO_20_00200 crossref_primary_10_2147_OTT_S377638 crossref_primary_10_1016_j_eururo_2020_10_016 crossref_primary_10_1007_s00120_023_02081_w crossref_primary_10_6004_jnccn_2020_5021 crossref_primary_10_1200_OP_20_00445 crossref_primary_10_1016_j_mtbio_2021_100189 crossref_primary_10_1016_j_ymthe_2022_08_019 crossref_primary_10_1016_j_adro_2021_100808 crossref_primary_10_1200_JCO_20_01755 crossref_primary_10_3389_fonc_2023_1165188 crossref_primary_10_1136_bmjopen_2019_034708 crossref_primary_10_1016_j_urolonc_2022_01_009 crossref_primary_10_1056_NEJMoa2022485 crossref_primary_10_4103_aja2022109 crossref_primary_10_1016_S0140_6736_21_00950_8 crossref_primary_10_1016_j_colsurfb_2023_113732 crossref_primary_10_1080_14737140_2021_1843430 crossref_primary_10_1200_PO_20_00424 crossref_primary_10_3390_curroncol29070400 crossref_primary_10_1007_s00092_019_3007_2 crossref_primary_10_4103_crst_crst_131_23 crossref_primary_10_1158_1078_0432_CCR_20_1981 crossref_primary_10_3389_fimmu_2022_1009634 crossref_primary_10_3390_cancers13184522 crossref_primary_10_1016_j_eururo_2022_08_022 crossref_primary_10_1158_1535_7163_MCT_22_0237 crossref_primary_10_1016_j_euf_2020_03_009 crossref_primary_10_1158_1078_0432_CCR_21_4302 crossref_primary_10_1016_j_ejca_2019_10_030 crossref_primary_10_3390_pharmaceutics15020662 crossref_primary_10_1016_j_euf_2020_03_003 crossref_primary_10_3390_ijms24032939 crossref_primary_10_1002_bco2_129 crossref_primary_10_1016_j_canlet_2021_06_010 crossref_primary_10_1016_j_ctrv_2024_102698 crossref_primary_10_1007_s00120_023_02212_3 crossref_primary_10_1007_s42399_021_00861_z crossref_primary_10_1016_j_eururo_2021_06_021 crossref_primary_10_1016_j_drup_2021_100761 crossref_primary_10_1097_SPC_0000000000000620 crossref_primary_10_1016_j_ejca_2023_05_008 crossref_primary_10_3390_ijms22041551 crossref_primary_10_1038_s41391_022_00588_5 crossref_primary_10_1016_j_clgc_2024_102138 crossref_primary_10_3389_fonc_2025_1530580 crossref_primary_10_3390_cancers16030482 crossref_primary_10_1080_14737140_2021_1856661 crossref_primary_10_1038_s41598_023_39626_0 crossref_primary_10_1016_j_eururo_2020_09_046 crossref_primary_10_1016_j_fpurol_2022_11_001 crossref_primary_10_3389_fphar_2021_789319 crossref_primary_10_1016_j_eururo_2022_08_005 crossref_primary_10_2967_jnumed_123_267006 crossref_primary_10_1002_cncr_35472 crossref_primary_10_1016_S1470_2045_23_00529_6 crossref_primary_10_1080_17512433_2023_2181783 crossref_primary_10_1111_bju_15227 crossref_primary_10_1016_j_eururo_2020_05_020 crossref_primary_10_1200_GO_20_00511 crossref_primary_10_3390_cancers14071728 crossref_primary_10_1016_j_clgc_2023_04_004 crossref_primary_10_1177_17588359231221337 crossref_primary_10_3390_cancers16091643 crossref_primary_10_4103_ijc_ijc_1145_21 crossref_primary_10_36290_xon_2024_030 crossref_primary_10_3390_jcm13030734 crossref_primary_10_1016_j_ejca_2025_115226 crossref_primary_10_1016_j_clgc_2020_02_003 crossref_primary_10_1016_j_eururo_2020_08_021 crossref_primary_10_3389_fonc_2022_877613 crossref_primary_10_1200_JCO_22_02639 crossref_primary_10_1200_JCO_21_02304 crossref_primary_10_1007_s11864_025_01302_y crossref_primary_10_1016_j_fjurol_2024_102710 crossref_primary_10_5348_100029Z15YO2023CR crossref_primary_10_1002_pros_24373 crossref_primary_10_3390_cancers16142520 crossref_primary_10_1177_10781552241264530 crossref_primary_10_1016_j_euo_2024_07_011 crossref_primary_10_1016_j_eururo_2020_05_004 crossref_primary_10_3389_fcell_2022_958180 crossref_primary_10_1001_jamanetworkopen_2021_10950 crossref_primary_10_3390_biomedicines11072084 crossref_primary_10_1158_1078_0432_CCR_20_4805 crossref_primary_10_1136_jitc_2022_005702 crossref_primary_10_1007_s40265_022_01703_5 crossref_primary_10_1016_j_esmoop_2021_100089 crossref_primary_10_1038_s41391_021_00487_1 crossref_primary_10_1158_0008_5472_CAN_18_3637 crossref_primary_10_5649_jjphcs_47_150 crossref_primary_10_1016_j_ejca_2021_09_029 crossref_primary_10_1016_j_acuroe_2020_10_007 crossref_primary_10_3390_cancers14092219 crossref_primary_10_1016_j_trecan_2023_06_009 crossref_primary_10_1016_j_ejca_2021_09_036 crossref_primary_10_2967_jnumed_124_267723 crossref_primary_10_1080_14737140_2023_2208352 crossref_primary_10_1007_s10147_021_01956_2 crossref_primary_10_2967_jnumed_123_267321 crossref_primary_10_1172_JCI178278 crossref_primary_10_1016_j_canlet_2021_11_033 crossref_primary_10_1016_j_yao_2021_02_022 crossref_primary_10_1007_s41669_024_00508_4 crossref_primary_10_3390_biochem3030009 crossref_primary_10_3389_fonc_2020_594023 crossref_primary_10_1007_s00120_023_02230_1 crossref_primary_10_1016_j_thromres_2020_12_016 crossref_primary_10_1002_uro2_76 crossref_primary_10_1186_s12885_021_08670_2 crossref_primary_10_1016_j_euo_2023_10_015 crossref_primary_10_1001_jamanetworkopen_2022_5394 crossref_primary_10_1016_j_urolonc_2022_09_011 crossref_primary_10_1007_s11912_022_01278_0 crossref_primary_10_1016_j_urolonc_2022_09_010 crossref_primary_10_1016_j_ccell_2020_08_007 crossref_primary_10_1038_s41391_021_00488_0 crossref_primary_10_3390_cancers14010147 crossref_primary_10_1200_JCO_23_00233 crossref_primary_10_20960_revcancer_00047 crossref_primary_10_1016_j_eururo_2024_04_010 crossref_primary_10_1038_s43018_020_00141_0 crossref_primary_10_1016_j_eururo_2024_10_003 crossref_primary_10_3390_ijms25094624 crossref_primary_10_1200_OP_24_00591 crossref_primary_10_3390_cancers15153969 crossref_primary_10_1007_s12672_022_00569_z crossref_primary_10_56969_oc_v28i1_136 crossref_primary_10_1038_s41391_025_00950_3 crossref_primary_10_3390_cancers12071750 crossref_primary_10_1016_j_fpurol_2024_07_205 crossref_primary_10_3390_diagnostics11020345 crossref_primary_10_1038_s41591_024_03204_2 crossref_primary_10_1016_S1761_3310_20_44713_9 crossref_primary_10_1038_s44276_024_00065_7 crossref_primary_10_1016_j_eururo_2021_08_011 crossref_primary_10_1111_iju_15052 crossref_primary_10_1007_s13139_022_00764_4 crossref_primary_10_3390_cancers14040907 crossref_primary_10_3390_ph13110409 crossref_primary_10_1016_j_clgc_2022_04_009 crossref_primary_10_2147_RRU_S385257 crossref_primary_10_1097_CU9_0000000000000217 crossref_primary_10_1016_j_clgc_2021_03_022 crossref_primary_10_1172_JCI161858 crossref_primary_10_17650_1726_9776_2020_16_1_66_77 crossref_primary_10_1186_s12885_025_13895_6 crossref_primary_10_1186_s12894_023_01233_6 crossref_primary_10_1186_s12885_020_07754_9 crossref_primary_10_3390_cancers12092568 crossref_primary_10_1016_j_esmoop_2022_100518 crossref_primary_10_1016_j_ijrobp_2022_05_037 crossref_primary_10_1016_j_mehy_2020_109639 crossref_primary_10_1200_EDBK_321209 crossref_primary_10_1007_s11033_022_07307_2 crossref_primary_10_1016_j_clgc_2020_08_008 crossref_primary_10_3390_diseases12070162 crossref_primary_10_3390_cancers16173098 crossref_primary_10_1016_j_euo_2024_08_007 crossref_primary_10_1080_14737140_2022_2020651 crossref_primary_10_1016_j_isci_2023_107409 crossref_primary_10_1080_21681805_2020_1730435 crossref_primary_10_1159_000519861 crossref_primary_10_3390_curroncol31090375 crossref_primary_10_1007_s00120_020_01177_x crossref_primary_10_1016_j_tem_2020_12_004 crossref_primary_10_1093_jjco_hyae003 crossref_primary_10_1007_s12094_021_02561_5 crossref_primary_10_1093_oncolo_oyac198 crossref_primary_10_1177_15330338211035260 crossref_primary_10_3390_cancers16030627 crossref_primary_10_1038_s41585_024_00875_x crossref_primary_10_1016_j_yexmp_2021_104607 crossref_primary_10_1186_s12913_022_08274_x crossref_primary_10_1200_EDBK_278845 crossref_primary_10_1007_s00120_020_01187_9 crossref_primary_10_1016_j_annonc_2021_04_016 crossref_primary_10_1016_j_eururo_2021_09_030 crossref_primary_10_1002_pros_24069 crossref_primary_10_1200_OP_24_00036 crossref_primary_10_1007_s12325_022_02085_6 crossref_primary_10_1038_s41391_022_00605_7 crossref_primary_10_1159_000513190 crossref_primary_10_2217_fon_2022_0914 crossref_primary_10_1016_j_annonc_2024_09_005 crossref_primary_10_1016_j_esmoop_2024_103446 crossref_primary_10_1016_S0140_6736_21_00237_3 crossref_primary_10_1177_15579883241285162 crossref_primary_10_2147_RRU_S360444 crossref_primary_10_1158_1078_0432_CCR_23_3436 crossref_primary_10_1016_j_euf_2024_09_017 crossref_primary_10_1055_a_1120_2823 crossref_primary_10_1001_jamanetworkopen_2024_33863 crossref_primary_10_3390_cancers12102855 crossref_primary_10_1016_j_annonc_2021_03_205 crossref_primary_10_1186_s12885_023_10998_w crossref_primary_10_3390_ijms222413519 crossref_primary_10_1016_j_med_2021_02_013 crossref_primary_10_1097_RLU_0000000000004763 crossref_primary_10_1126_sciadv_abi8193 crossref_primary_10_1016_j_esmoop_2021_100241 crossref_primary_10_1093_oncolo_oyac048 crossref_primary_10_1016_j_eururo_2022_02_022 crossref_primary_10_1111_iju_70019 crossref_primary_10_1097_MOU_0000000000001080 crossref_primary_10_1056_NEJMe1912750 crossref_primary_10_1001_jamanetworkopen_2024_45505 crossref_primary_10_1007_s15004_024_0719_6 crossref_primary_10_6004_jnccn_2021_0008 crossref_primary_10_1200_PO_19_00399 crossref_primary_10_1002_pros_24270 crossref_primary_10_1200_JCO_24_01283 crossref_primary_10_1016_j_bulcan_2023_03_012 crossref_primary_10_1038_s41598_024_75589_6 crossref_primary_10_1007_s00120_020_01381_9 crossref_primary_10_1016_S1470_2045_19_30743_0 crossref_primary_10_2139_ssrn_3924205 crossref_primary_10_2217_fon_2020_0672 crossref_primary_10_3389_fonc_2021_732599 crossref_primary_10_1038_s41585_021_00438_4 crossref_primary_10_1002_pros_24138 crossref_primary_10_1038_s41391_020_00308_x crossref_primary_10_1080_10408363_2023_2266482 crossref_primary_10_1158_1078_0432_CCR_22_0612 crossref_primary_10_1016_j_eururo_2023_05_009 crossref_primary_10_7759_cureus_34490 crossref_primary_10_1186_s13046_024_03064_1 crossref_primary_10_1200_PO_24_00645 crossref_primary_10_3389_fimmu_2022_842038 crossref_primary_10_1002_pros_24048 crossref_primary_10_1016_j_clgc_2021_11_007 crossref_primary_10_1093_jjco_hyab028 crossref_primary_10_1007_s12020_022_03166_w crossref_primary_10_1200_OP_20_00908 crossref_primary_10_3390_ijms25042184 crossref_primary_10_1016_j_eclinm_2021_100887 crossref_primary_10_1016_j_mednuc_2023_09_003 crossref_primary_10_1097_CCO_0000000000000624 crossref_primary_10_1007_s11523_024_01117_1 crossref_primary_10_1016_j_esmoop_2024_103009 crossref_primary_10_1007_s00120_020_01306_6 crossref_primary_10_3390_biomedicines9040339 crossref_primary_10_1002_pros_24053 crossref_primary_10_1007_s00259_025_07076_7 crossref_primary_10_1111_iju_15458 crossref_primary_10_1002_pros_24056 crossref_primary_10_1016_j_ctarc_2020_100193 crossref_primary_10_1093_oncolo_oyab045 crossref_primary_10_26442_18151434_2021_3_201201 crossref_primary_10_3390_ijms22094712 crossref_primary_10_3390_app12105059 crossref_primary_10_3389_fonc_2020_00495 crossref_primary_10_1200_OP_21_00206 crossref_primary_10_1016_j_clgc_2025_102317 crossref_primary_10_3390_cancers15020461 crossref_primary_10_3390_ijms222312777 crossref_primary_10_2174_1568009622666220330194149 crossref_primary_10_1002_bco2_455 crossref_primary_10_1016_j_ctrv_2023_102525 crossref_primary_10_1016_j_annonc_2021_06_005 crossref_primary_10_1016_S1470_2045_20_30449_6 crossref_primary_10_1016_j_ctrv_2023_102524 crossref_primary_10_3390_cancers13164023 crossref_primary_10_3390_curroncol30080529 crossref_primary_10_1200_OP_21_00614 crossref_primary_10_1016_j_eururo_2020_01_012 crossref_primary_10_1016_j_acuro_2020_06_007 crossref_primary_10_1016_j_eururo_2020_01_018 crossref_primary_10_1016_j_mbs_2022_108940 crossref_primary_10_3389_fphar_2024_1451957 crossref_primary_10_1016_j_urolonc_2022_06_018 crossref_primary_10_1055_a_2295_8720 crossref_primary_10_3390_cancers14174276 crossref_primary_10_1016_S0140_6736_21_00349_4 crossref_primary_10_1038_s41391_022_00493_x crossref_primary_10_1007_s10147_024_02501_7 crossref_primary_10_1016_j_ctrv_2022_102359 crossref_primary_10_1016_j_urolonc_2021_04_016 crossref_primary_10_2967_jnumed_124_269252 crossref_primary_10_1080_14796694_2025_2470616 crossref_primary_10_1007_s00761_024_01547_6 crossref_primary_10_3390_ijms23052569 crossref_primary_10_1177_17562872241272929 crossref_primary_10_1007_s00120_019_01086_8 crossref_primary_10_1080_03007995_2024_2395435 crossref_primary_10_1111_ajco_13441 crossref_primary_10_3389_fendo_2022_1006101 crossref_primary_10_1038_s41388_020_01557_9 crossref_primary_10_3389_fmed_2024_1460212 crossref_primary_10_1016_S1470_2045_22_00092_4 crossref_primary_10_1093_jjco_hyaf034 crossref_primary_10_1097_MOU_0000000000000775 crossref_primary_10_1055_a_1247_4155 crossref_primary_10_1080_14656566_2023_2244415 crossref_primary_10_1016_j_eclinm_2025_103129 crossref_primary_10_1111_iju_14725 crossref_primary_10_1016_j_urolonc_2022_11_019 crossref_primary_10_1016_j_euo_2024_03_013 crossref_primary_10_1016_j_eururo_2022_04_002 crossref_primary_10_1016_j_adro_2024_101655 crossref_primary_10_1038_s41391_020_0222_6 crossref_primary_10_3390_pharmaceutics14081539 crossref_primary_10_1177_17588359241305084 crossref_primary_10_1016_j_clgc_2024_102188 crossref_primary_10_1007_s00761_021_01024_4 crossref_primary_10_1200_GO_22_00154 crossref_primary_10_1097_CCO_0000000000001128 crossref_primary_10_1158_1078_0432_CCR_21_1625 crossref_primary_10_2217_fon_2020_1133 crossref_primary_10_1097_MOU_0000000000000784 crossref_primary_10_1016_j_canlet_2021_08_033 crossref_primary_10_1016_j_euf_2024_07_013 crossref_primary_10_3390_cancers14030503 crossref_primary_10_1016_S1166_7087_20_30752_1 crossref_primary_10_1002_jmri_27485 crossref_primary_10_1016_j_banm_2023_11_018 crossref_primary_10_2174_1568009620666201021163919 crossref_primary_10_1177_17588359221100022 crossref_primary_10_1186_s13062_022_00318_w crossref_primary_10_3390_curroncol31020078 crossref_primary_10_1016_j_adro_2024_101507 crossref_primary_10_3390_cancers13194951 crossref_primary_10_1016_j_eururo_2020_02_020 crossref_primary_10_1016_j_eururo_2024_09_017 crossref_primary_10_1038_s41391_024_00906_z crossref_primary_10_1200_PO_24_00014 crossref_primary_10_1016_j_ejca_2022_06_057 crossref_primary_10_1007_s40487_021_00181_1 crossref_primary_10_1016_j_bulcan_2020_11_010 crossref_primary_10_1016_j_eururo_2021_10_016 crossref_primary_10_1158_2159_8290_CD_20_1301 crossref_primary_10_1371_journal_pone_0264800 crossref_primary_10_2217_fon_2020_1008 crossref_primary_10_1016_j_jgo_2024_101750 crossref_primary_10_5534_wjmh_220200 crossref_primary_10_2217_fon_2020_1245 crossref_primary_10_1016_j_bulcan_2020_11_016 crossref_primary_10_1016_j_euros_2024_06_010 crossref_primary_10_4103_iju_iju_83_24 crossref_primary_10_1016_j_clgc_2023_02_010 crossref_primary_10_1186_s13045_021_01061_x crossref_primary_10_3390_biomedicines9081042 crossref_primary_10_1016_j_eururo_2024_09_008 crossref_primary_10_3389_fonc_2024_1355551 crossref_primary_10_1016_j_trecan_2020_04_010 crossref_primary_10_1007_s00120_020_01411_6 crossref_primary_10_2147_OTT_S228355 crossref_primary_10_1056_NEJMc2000990 crossref_primary_10_1111_ajco_13732 crossref_primary_10_1016_j_bbcan_2023_188887 crossref_primary_10_2967_jnumed_123_265952 crossref_primary_10_1016_j_eururo_2021_03_001 crossref_primary_10_1038_s41391_020_00299_9 crossref_primary_10_3390_cancers13061284 crossref_primary_10_3389_fonc_2022_877380 crossref_primary_10_1080_14656566_2020_1767069 crossref_primary_10_1016_j_euo_2020_10_004 crossref_primary_10_1200_GO_24_00042 crossref_primary_10_17650_1726_9776_2022_18_1_90_105 crossref_primary_10_2174_1389203723666220705152713 crossref_primary_10_2217_fon_2020_1104 crossref_primary_10_1016_j_annonc_2023_02_015 crossref_primary_10_3389_fonc_2023_1240864 crossref_primary_10_1016_j_annonc_2020_06_011 crossref_primary_10_2147_CMAR_S335962 crossref_primary_10_1016_j_eururo_2021_10_029 crossref_primary_10_2217_fon_2020_0361 crossref_primary_10_1097_MOU_0000000000000984 crossref_primary_10_1097_MOU_0000000000000985 crossref_primary_10_2147_CMAR_S270392 crossref_primary_10_1016_j_eururo_2020_02_025 crossref_primary_10_1158_1541_7786_MCR_20_0975 crossref_primary_10_1016_S1470_2045_21_00402_2 |
| Cites_doi | 10.1016/j.critrevonc.2015.07.013 10.1111/iju.13346 10.1016/j.eururo.2016.06.033 10.1056/NEJMoa1315815 10.1002/pros.23246 10.1111/j.1526-4637.2009.00774.x 10.1056/NEJMoa1815671 10.1016/j.ejca.2015.07.037 10.1016/S0140-6736(15)01037-5 10.1056/NEJMoa1903835 10.1016/j.eururo.2014.04.015 10.1016/j.eururo.2014.11.033 10.1056/NEJMoa1715546 10.1056/NEJMoa1704174 10.1016/S0140-6736(10)61389-X 10.1200/JCO.2016.72.1076 10.1016/j.ejca.2019.05.007 10.1093/annonc/mdz051 10.1056/NEJMoa1800536 10.1200/JCO.2018.77.9827 10.3322/caac.21551 10.1158/1535-7163.MCT-14-0265 10.1056/NEJMoa040720 10.1056/NEJMoa1903307 10.1093/annonc/mds119 10.1200/JCO.2014.55.3875 10.1056/NEJMoa1503747 10.1016/j.clgc.2016.12.015 10.1056/NEJMoa1213755 10.1016/j.euo.2018.05.009 10.1016/j.urolonc.2018.08.002 10.1016/j.eururo.2013.07.022 10.1056/NEJMoa1014618 10.1056/NEJMoa1207506 10.1200/JCO.2016.72.1068 10.1016/j.ejca.2014.01.006 10.1056/NEJMoa1001294 10.1056/NEJMoa1702900 10.1016/j.euo.2018.02.006 10.1093/annonc/mdt136 10.1001/jamaoncol.2015.1341 10.1016/S1470-2045(17)30605-8 10.1002/pros.23182 10.1200/JCO.2007.12.4487 |
| ContentType | Journal Article |
| Contributor | Pinto, Alvaro Iacovelli, Roberto van Oort, Inge Melichar, Bohuslav Pérez Valderrama, Begoña Schostak, Martin Verschaeve, Vincent Sternberg, Cora Westgeest, Hans Peters, Frank Ritter, Manuel Duran, Ignacio McDermott, Ray Welslau, Manfred Barthelemy, Philippe Mahammedi, Hakim Fizazi, Karim Gasparro, Donatello Eymard, Jean-Christophe Loidl, Wolfgang Galceran, Joan Carles Hellmis, Eva Maeseneer, Daan De Krainer, Michael Kocak, Ivo Merseburger, Axel Finek, Jindrich Matouskova, Michaela Bögemann, Martin Aglietta, Massimo Kramer, Gero Feyerabend, Susan Théodore, Christine Ertl, Sebastian de Wit, Ronald Dumez, Herlinde Castellano, Daniel Hardy-Bessard, Anne-Claire Tombal, Bertrand Helissey, Carole Berruti, Alfredo Strauss, Arne Gil, Thierry Wülfing, Christian Culine, Stephane Hübner, Andreas Azria, David Papandreou, Christos Bamias, Aristotelis Nuhn, Philipp Efstathiou, Eleni Gravis, Gwenaëlle Koenig, Franck Facchini, Gaetano Knobel, Heidi Martinez Chanza, Nieves Falcone, Alfredo Rottey, Sylvie Linassier, Claude Grimm, Marc-Oliver McCaffey, John Stensvo |
| Contributor_xml | – sequence: 1 givenname: Michael surname: Krainer fullname: Krainer, Michael – sequence: 2 givenname: Gero surname: Kramer fullname: Kramer, Gero – sequence: 3 givenname: Wolfgang surname: Loidl fullname: Loidl, Wolfgang – sequence: 4 givenname: Daan De surname: Maeseneer fullname: Maeseneer, Daan De – sequence: 5 givenname: Herlinde surname: Dumez fullname: Dumez, Herlinde – sequence: 6 givenname: Thierry surname: Gil fullname: Gil, Thierry – sequence: 7 givenname: Nieves surname: Martinez Chanza fullname: Martinez Chanza, Nieves – sequence: 8 givenname: Sylvie surname: Rottey fullname: Rottey, Sylvie – sequence: 9 givenname: Vincent surname: Verschaeve fullname: Verschaeve, Vincent – sequence: 10 givenname: Bertrand surname: Tombal fullname: Tombal, Bertrand – sequence: 11 givenname: Jindrich surname: Finek fullname: Finek, Jindrich – sequence: 12 givenname: Ivo surname: Kocak fullname: Kocak, Ivo – sequence: 13 givenname: Bohuslav surname: Melichar fullname: Melichar, Bohuslav – sequence: 14 givenname: Michaela surname: Matouskova fullname: Matouskova, Michaela – sequence: 15 givenname: David surname: Azria fullname: Azria, David – sequence: 16 givenname: Philippe surname: Barthelemy fullname: Barthelemy, Philippe – sequence: 17 givenname: Stephane surname: Culine fullname: Culine, Stephane – sequence: 18 givenname: Jean-Christophe surname: Eymard fullname: Eymard, Jean-Christophe – sequence: 19 givenname: Karim surname: Fizazi fullname: Fizazi, Karim – sequence: 20 givenname: Aude surname: Flechon fullname: Flechon, Aude – sequence: 21 givenname: Gwenaëlle surname: Gravis fullname: Gravis, Gwenaëlle – sequence: 22 givenname: Anne-Claire surname: Hardy-Bessard fullname: Hardy-Bessard, Anne-Claire – sequence: 23 givenname: Carole surname: Helissey fullname: Helissey, Carole – sequence: 24 givenname: Claude surname: Linassier fullname: Linassier, Claude – sequence: 25 givenname: Hakim surname: Mahammedi fullname: Mahammedi, Hakim – sequence: 26 givenname: Stéphane surname: Oudard fullname: Oudard, Stéphane – sequence: 27 givenname: Christine surname: Théodore fullname: Théodore, Christine – sequence: 28 givenname: Martin surname: Bögemann fullname: Bögemann, Martin – sequence: 29 givenname: Sebastian surname: Ertl fullname: Ertl, Sebastian – sequence: 30 givenname: Susan surname: Feyerabend fullname: Feyerabend, Susan – sequence: 31 givenname: Marc-Oliver surname: Grimm fullname: Grimm, Marc-Oliver – sequence: 32 givenname: Eva surname: Hellmis fullname: Hellmis, Eva – sequence: 33 givenname: Andreas surname: Hübner fullname: Hübner, Andreas – sequence: 34 givenname: Franck surname: Koenig fullname: Koenig, Franck – sequence: 35 givenname: Axel surname: Merseburger fullname: Merseburger, Axel – sequence: 36 givenname: Philipp surname: Nuhn fullname: Nuhn, Philipp – sequence: 37 givenname: Manuel surname: Ritter fullname: Ritter, Manuel – sequence: 38 givenname: Martin surname: Schostak fullname: Schostak, Martin – sequence: 39 givenname: Arne surname: Strauss fullname: Strauss, Arne – sequence: 40 givenname: Manfred surname: Welslau fullname: Welslau, Manfred – sequence: 41 givenname: Christian surname: Wülfing fullname: Wülfing, Christian – sequence: 42 givenname: Aristotelis surname: Bamias fullname: Bamias, Aristotelis – sequence: 43 givenname: Eleni surname: Efstathiou fullname: Efstathiou, Eleni – sequence: 44 givenname: Christos surname: Papandreou fullname: Papandreou, Christos – sequence: 45 givenname: Asgerdur surname: Sverrisdottir fullname: Sverrisdottir, Asgerdur – sequence: 46 givenname: John surname: McCaffey fullname: McCaffey, John – sequence: 47 givenname: Ray surname: McDermott fullname: McDermott, Ray – sequence: 48 givenname: Massimo surname: Aglietta fullname: Aglietta, Massimo – sequence: 49 givenname: Alfredo surname: Berruti fullname: Berruti, Alfredo – sequence: 50 givenname: Donatello surname: Gasparro fullname: Gasparro, Donatello – sequence: 51 givenname: Gaetano surname: Facchini fullname: Facchini, Gaetano – sequence: 52 givenname: Alfredo surname: Falcone fullname: Falcone, Alfredo – sequence: 53 givenname: Roberto surname: Iacovelli fullname: Iacovelli, Roberto – sequence: 54 givenname: Cora surname: Sternberg fullname: Sternberg, Cora – sequence: 55 givenname: Heidi surname: Knobel fullname: Knobel, Heidi – sequence: 56 givenname: Andreas surname: Stensvold fullname: Stensvold, Andreas – sequence: 57 givenname: Daniel surname: Castellano fullname: Castellano, Daniel – sequence: 58 givenname: Ignacio surname: Duran fullname: Duran, Ignacio – sequence: 59 givenname: Joan Carles surname: Galceran fullname: Galceran, Joan Carles – sequence: 60 givenname: Begoña surname: Pérez Valderrama fullname: Pérez Valderrama, Begoña – sequence: 61 givenname: Alvaro surname: Pinto fullname: Pinto, Alvaro – sequence: 62 givenname: Ronald surname: de Wit fullname: de Wit, Ronald – sequence: 63 givenname: Frank surname: Peters fullname: Peters, Frank – sequence: 64 givenname: Inge surname: van Oort fullname: van Oort, Inge – sequence: 65 givenname: Hans surname: Westgeest fullname: Westgeest, Hans |
| Copyright | Copyright © 2019 Massachusetts Medical Society. All rights reserved. Copyright © 2019 Massachusetts Medical Society. |
| Copyright_xml | – notice: Copyright © 2019 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2019 Massachusetts Medical Society. |
| CorporateAuthor | CARD Investigators |
| CorporateAuthor_xml | – name: CARD Investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
| DOI | 10.1056/NEJMoa1911206 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database (subscription) Healthcare Administration Database PML(ProQuest Medical Library) Psychology Database Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: Proquest Central Journals url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 2518 |
| ExternalDocumentID | 31566937 10_1056_NEJMoa1911206 NJ201912263812606 |
| Genre | Original Article Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | - 0R 0WA 123 186 1VV 29N 2KS 2WC 34G 39C 4 4.4 53G 55 5RE 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACRZS ADBBV ADBIT ADCBC ADRHT AENEX AETEA AFFNX AFHKK AFKRA AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS ET EX3 F5P FD8 FM. FYUFA GJ GNUQQ GUQSH HCIFZ HZ I4R IH2 K-O KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MVM N9A NAPCQ NEJ O9- OK1 OMK OVD P-O P-S P2P PADUT PCD PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TEORI TN5 TUQ TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZR0 --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 36B AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ACKOT ACPFK ADUKH AERZD AFOSN AGHSJ ALIPV BYPQX CCPQU CITATION H13 HF~ HMCUK HZ~ N4W PHGZM PHGZT PSYQQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM CGR CUY CVF ECM EIF NPM UIG 7XB BEC K0Y MBDVC PJZUB PKEHL PPXIY PQGLB PUEGO Q9U 7X8 |
| ID | FETCH-LOGICAL-c456t-d5ac9ce2b44e3caf88e9163f92c148b02493148ecf74f01006bda12d9aba3b03 |
| IEDL.DBID | 7X7 |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Thu Jul 10 17:44:34 EDT 2025 Sat Aug 23 14:00:00 EDT 2025 Thu Apr 03 07:01:48 EDT 2025 Thu Apr 24 23:12:03 EDT 2025 Tue Jul 01 01:43:28 EDT 2025 Tue Dec 21 14:38:55 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 26 |
| Language | English |
| License | http://www.nejmgroup.org/legal/terms-of-use.htm Copyright © 2019 Massachusetts Medical Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c456t-d5ac9ce2b44e3caf88e9163f92c148b02493148ecf74f01006bda12d9aba3b03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-2034-595X |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1911206?articleTools=true |
| PMID | 31566937 |
| PQID | 2330624583 |
| PQPubID | 40644 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2299457633 proquest_journals_2330624583 pubmed_primary_31566937 crossref_primary_10_1056_NEJMoa1911206 crossref_citationtrail_10_1056_NEJMoa1911206 mms_nejm_10_1056_NEJMoa1911206 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20191226 2019-12-26 |
| PublicationDateYYYYMMDD | 2019-12-26 |
| PublicationDate_xml | – month: 12 year: 2019 text: 20191226 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2019 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | Al Nakouzi, N, Le Moulec, S, Albigès, L (r034) 2015; 68 de Bono, JS, Logothetis, CJ, Molina, A (r006) 2011; 364 Delanoy, N, Hardy-Bessard, A-C, Efstathiou, E (r044) 2018; 1 Maughan, BL, Luber, B, Nadal, R, Antonarakis, ES (r041) 2017; 77 Oh, WK, Cheng, WY, Miao, R (r025) 2018; 36 Morris, MJ, Molina, A, Small, EJ (r040) 2015; 33 Sweeney, CJ, Chen, YH, Carducci, M (r009) 2015; 373 Antonarakis, ES, Lu, C, Luber, B (r031) 2015; 1 Fizazi, K, Shore, N, Tammela, TL (r017) 2019; 380 Eisenberger, M, Hardy-Bessard, AC, Kim, CS (r020) 2017; 35 Kantoff, PW, Higano, CS, Shore, ND (r005) 2010; 363 de Bono, JS, Smith, MR, Saad, F (r035) 2017; 71 Davis, ID, Martin, AJ, Stockler, MR (r013) 2019; 381 Oudard, S, Fizazi, K, Sengeløv, L (r021) 2017; 35 Atkinson, TM, Mendoza, TR, Sit, L (r028) 2010; 11 Attard, G, Borre, M, Gurney, H (r024) 2018; 36 Heidenreich, A, Bracarda, S, Mason, M (r038) 2014; 50 Siegel, RL, Miller, KD, Jemal, A (r001) 2019; 69 Mezynski, J, Pezaro, C, Bianchini, D (r026) 2012; 23 Malvezzi, M, Carioli, G, Bertuccio, P (r002) 2019; 30 Tannock, IF, de Wit, R, Berry, WR (r003) 2004; 351 Conteduca, V, Castro, E, Wetterskog, D (r033) 2019; 116 James, ND, de Bono, JS, Spears, MR (r012) 2017; 377 Azarenko, O, Smiyun, G, Mah, J, Wilson, L, Jordan, MA (r036) 2014; 13 Hussain, M, Fizazi, K, Saad, F (r015) 2018; 378 Parker, C, Nilsson, S, Heinrich, D (r008) 2013; 369 Antonarakis, ES, Lu, C, Wang, H (r030) 2014; 371 Beer, TM, Hotte, SJ, Saad, F (r039) 2017; 18 James, ND, Sydes, MR, Clarke, NW (r010) 2016; 387 Miyake, H, Hara, T, Tamura, K (r043) 2017; 15 Fizazi, K, Tran, N, Fein, L (r011) 2017; 377 van Soest, RJ, Nieuweboer, AJ, de Morrée, ES (r019) 2015; 51 Smith, MR, Saad, F, Chowdhury, S (r016) 2018; 378 Terada, N, Maughan, BL, Akamatsu, S (r042) 2017; 24 de Morrée, E, van Soest, R, Aghai, A (r037) 2016; 76 Loriot, Y, Bianchini, D, Ileana, E (r022) 2013; 24 van Soest, RJ, de Morrée, ES, Kweldam, CF (r018) 2015; 67 Maines, F, Caffo, O, Veccia, A (r023) 2015; 96 de Bono, JS, Oudard, S, Ozguroglu, M (r004) 2010; 376 Scher, HI, Fizazi, K, Saad, F (r007) 2012; 367 Fitzpatrick, JM, de Wit, R (r029) 2014; 65 Chi, KN, Agarwal, N, Bjartell, A (r014) 2019; 381 Rescigno, P, Lorente, D, Dolling, D (r032) 2018; 1 Scher, HI, Halabi, S, Tannock, I (r027) 2008; 26 e_1_3_5_28_2 e_1_3_5_27_2 e_1_3_5_26_2 e_1_3_5_25_2 e_1_3_5_24_2 e_1_3_5_23_2 e_1_3_5_22_2 e_1_3_5_21_2 e_1_3_5_43_2 e_1_3_5_44_2 e_1_3_5_45_2 e_1_3_5_29_2 e_1_3_5_2_2 e_1_3_5_40_2 e_1_3_5_41_2 e_1_3_5_42_2 e_1_3_5_8_2 e_1_3_5_20_2 e_1_3_5_7_2 e_1_3_5_9_2 e_1_3_5_4_2 e_1_3_5_3_2 e_1_3_5_6_2 e_1_3_5_5_2 e_1_3_5_17_2 e_1_3_5_39_2 e_1_3_5_16_2 e_1_3_5_38_2 e_1_3_5_15_2 e_1_3_5_37_2 e_1_3_5_14_2 e_1_3_5_36_2 e_1_3_5_12_2 e_1_3_5_35_2 e_1_3_5_13_2 e_1_3_5_34_2 e_1_3_5_10_2 e_1_3_5_33_2 e_1_3_5_11_2 e_1_3_5_32_2 e_1_3_5_19_2 e_1_3_5_18_2 e_1_3_5_31_2 e_1_3_5_30_2 32212535 - N Engl J Med. 2020 Mar 26;382(13):1286 32029338 - Eur Urol. 2020 Apr;77(4):560-561 32209284 - Eur Urol. 2020 Jun;77(6):758-759 31928459 - J Urol. 2020 Apr;203(4):662-663 31881143 - N Engl J Med. 2019 Dec 26;381(26):2564-2566 |
| References_xml | – volume: 387 start-page: 1163 year: 2016 end-page: 1177 ident: r010 article-title: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. publication-title: Lancet – volume: 26 start-page: 1148 year: 2008 end-page: 1159 ident: r027 article-title: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. publication-title: J Clin Oncol – volume: 76 start-page: 927 year: 2016 end-page: 936 ident: r037 article-title: Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation. publication-title: Prostate – volume: 18 start-page: 1532 year: 2017 end-page: 1542 ident: r039 article-title: Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. publication-title: Lancet Oncol – volume: 378 start-page: 1408 year: 2018 end-page: 1418 ident: r016 article-title: Apalutamide treatment and metastasis-free survival in prostate cancer. publication-title: N Engl J Med – volume: 351 start-page: 1502 year: 2004 end-page: 1512 ident: r003 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. publication-title: N Engl J Med – volume: 36 start-page: 2639 year: 2018 end-page: 2646 ident: r024 article-title: Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. publication-title: J Clin Oncol – volume: 23 start-page: 2943 year: 2012 end-page: 2947 ident: r026 article-title: Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? publication-title: Ann Oncol – volume: 381 start-page: 121 year: 2019 end-page: 131 ident: r013 article-title: Enzalutamide with standard first-line therapy in metastatic prostate cancer. publication-title: N Engl J Med – volume: 371 start-page: 1028 year: 2014 end-page: 1038 ident: r030 article-title: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. publication-title: N Engl J Med – volume: 69 start-page: 7 year: 2019 end-page: 34 ident: r001 article-title: Cancer statistics, 2019. publication-title: CA Cancer J Clin – volume: 380 start-page: 1235 year: 2019 end-page: 1246 ident: r017 article-title: Darolutamide in nonmetastatic, castration-resistant prostate cancer. publication-title: N Engl J Med – volume: 1 start-page: 582 year: 2015 end-page: 591 ident: r031 article-title: Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. publication-title: JAMA Oncol – volume: 364 start-page: 1995 year: 2011 end-page: 2005 ident: r006 article-title: Abiraterone and increased survival in metastatic prostate cancer. publication-title: N Engl J Med – volume: 77 start-page: 33 year: 2017 end-page: 40 ident: r041 article-title: Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. publication-title: Prostate – volume: 35 start-page: 3189 year: 2017 end-page: 3197 ident: r021 article-title: Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial — FIRSTANA. publication-title: J Clin Oncol – volume: 11 start-page: 337 year: 2010 end-page: 346 ident: r028 article-title: The Brief Pain Inventory and its “pain at its worst in the last 24 hours” item: clinical trial endpoint considerations. publication-title: Pain Med – volume: 24 start-page: 441 year: 2017 end-page: 448 ident: r042 article-title: Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. publication-title: Int J Urol – volume: 33 start-page: 1356 year: 2015 end-page: 1363 ident: r040 article-title: Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. publication-title: J Clin Oncol – volume: 1 start-page: 71 year: 2018 end-page: 77 ident: r032 article-title: Docetaxel treatment in PTEN- and ERG-aberrant metastatic prostate cancers. publication-title: Eur Urol Oncol – volume: 363 start-page: 411 year: 2010 end-page: 422 ident: r005 article-title: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. publication-title: N Engl J Med – volume: 65 start-page: 1198 year: 2014 end-page: 1204 ident: r029 article-title: Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. publication-title: Eur Urol – volume: 36 start-page: 500.e1 issue: 11 year: 2018 end-page: 500.e9 ident: r025 article-title: Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. publication-title: Urol Oncol – volume: 68 start-page: 228 year: 2015 end-page: 235 ident: r034 article-title: Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. publication-title: Eur Urol – volume: 376 start-page: 1147 year: 2010 end-page: 1154 ident: r004 article-title: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. publication-title: Lancet – volume: 30 start-page: 781 year: 2019 end-page: 787 ident: r002 article-title: European cancer mortality predictions for the year 2019 with focus on breast cancer. publication-title: Ann Oncol – volume: 13 start-page: 2092 year: 2014 end-page: 2103 ident: r036 article-title: Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells. publication-title: Mol Cancer Ther – volume: 367 start-page: 1187 year: 2012 end-page: 1197 ident: r007 article-title: Increased survival with enzalutamide in prostate cancer after chemotherapy. publication-title: N Engl J Med – volume: 96 start-page: 498 year: 2015 end-page: 506 ident: r023 article-title: Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. publication-title: Crit Rev Oncol Hematol – volume: 116 start-page: 158 year: 2019 end-page: 168 ident: r033 article-title: Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. publication-title: Eur J Cancer – volume: 1 start-page: 467 year: 2018 end-page: 475 ident: r044 article-title: Sequencing of taxanes and new androgen-targeted therapies in metastatic castration-resistant prostate cancer: results of the international multicentre retrospective CATS database. publication-title: Eur Urol Oncol – volume: 71 start-page: 656 year: 2017 end-page: 664 ident: r035 article-title: Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. publication-title: Eur Urol – volume: 67 start-page: 981 year: 2015 end-page: 985 ident: r018 article-title: Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. publication-title: Eur Urol – volume: 50 start-page: 1090 year: 2014 end-page: 1099 ident: r038 article-title: Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. publication-title: Eur J Cancer – volume: 51 start-page: 2562 year: 2015 end-page: 2569 ident: r019 article-title: The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. publication-title: Eur J Cancer – volume: 35 start-page: 3198 year: 2017 end-page: 3206 ident: r020 article-title: Phase III study comparing a reduced dose of cabazitaxel (20 mg/m ) and the currently approved dose (25 mg/m ) in postdocetaxel patients with metastatic castration-resistant prostate cancer — PROSELICA. publication-title: J Clin Oncol – volume: 377 start-page: 338 year: 2017 end-page: 351 ident: r012 article-title: Abiraterone for prostate cancer not previously treated with hormone therapy. publication-title: N Engl J Med – volume: 378 start-page: 2465 year: 2018 end-page: 2474 ident: r015 article-title: Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. publication-title: N Engl J Med – volume: 373 start-page: 737 year: 2015 end-page: 746 ident: r009 article-title: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. publication-title: N Engl J Med – volume: 24 start-page: 1807 year: 2013 end-page: 1812 ident: r022 article-title: Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). publication-title: Ann Oncol – volume: 369 start-page: 213 year: 2013 end-page: 223 ident: r008 article-title: Alpha emitter radium-223 and survival in metastatic prostate cancer. publication-title: N Engl J Med – volume: 377 start-page: 352 year: 2017 end-page: 360 ident: r011 article-title: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. publication-title: N Engl J Med – volume: 381 start-page: 13 year: 2019 end-page: 24 ident: r014 article-title: Apalutamide for metastatic, castration-sensitive prostate cancer. publication-title: N Engl J Med – volume: 15 start-page: e591 issue: 4 year: 2017 end-page: e597 ident: r043 article-title: Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. publication-title: Clin Genitourin Cancer – ident: e_1_3_5_24_2 doi: 10.1016/j.critrevonc.2015.07.013 – ident: e_1_3_5_43_2 doi: 10.1111/iju.13346 – ident: e_1_3_5_36_2 doi: 10.1016/j.eururo.2016.06.033 – ident: e_1_3_5_31_2 doi: 10.1056/NEJMoa1315815 – ident: e_1_3_5_42_2 doi: 10.1002/pros.23246 – ident: e_1_3_5_29_2 doi: 10.1111/j.1526-4637.2009.00774.x – ident: e_1_3_5_18_2 doi: 10.1056/NEJMoa1815671 – ident: e_1_3_5_20_2 doi: 10.1016/j.ejca.2015.07.037 – ident: e_1_3_5_11_2 doi: 10.1016/S0140-6736(15)01037-5 – ident: e_1_3_5_14_2 doi: 10.1056/NEJMoa1903835 – ident: e_1_3_5_35_2 doi: 10.1016/j.eururo.2014.04.015 – ident: e_1_3_5_19_2 doi: 10.1016/j.eururo.2014.11.033 – ident: e_1_3_5_17_2 doi: 10.1056/NEJMoa1715546 – ident: e_1_3_5_12_2 doi: 10.1056/NEJMoa1704174 – ident: e_1_3_5_5_2 doi: 10.1016/S0140-6736(10)61389-X – ident: e_1_3_5_21_2 doi: 10.1200/JCO.2016.72.1076 – ident: e_1_3_5_34_2 doi: 10.1016/j.ejca.2019.05.007 – ident: e_1_3_5_3_2 doi: 10.1093/annonc/mdz051 – ident: e_1_3_5_16_2 doi: 10.1056/NEJMoa1800536 – ident: e_1_3_5_25_2 doi: 10.1200/JCO.2018.77.9827 – ident: e_1_3_5_2_2 doi: 10.3322/caac.21551 – ident: e_1_3_5_37_2 doi: 10.1158/1535-7163.MCT-14-0265 – ident: e_1_3_5_4_2 doi: 10.1056/NEJMoa040720 – ident: e_1_3_5_15_2 doi: 10.1056/NEJMoa1903307 – ident: e_1_3_5_27_2 doi: 10.1093/annonc/mds119 – ident: e_1_3_5_41_2 doi: 10.1200/JCO.2014.55.3875 – ident: e_1_3_5_10_2 doi: 10.1056/NEJMoa1503747 – ident: e_1_3_5_44_2 doi: 10.1016/j.clgc.2016.12.015 – ident: e_1_3_5_9_2 doi: 10.1056/NEJMoa1213755 – ident: e_1_3_5_45_2 doi: 10.1016/j.euo.2018.05.009 – ident: e_1_3_5_26_2 doi: 10.1016/j.urolonc.2018.08.002 – ident: e_1_3_5_30_2 doi: 10.1016/j.eururo.2013.07.022 – ident: e_1_3_5_7_2 doi: 10.1056/NEJMoa1014618 – ident: e_1_3_5_8_2 doi: 10.1056/NEJMoa1207506 – ident: e_1_3_5_22_2 doi: 10.1200/JCO.2016.72.1068 – ident: e_1_3_5_39_2 doi: 10.1016/j.ejca.2014.01.006 – ident: e_1_3_5_6_2 doi: 10.1056/NEJMoa1001294 – ident: e_1_3_5_13_2 doi: 10.1056/NEJMoa1702900 – ident: e_1_3_5_33_2 doi: 10.1016/j.euo.2018.02.006 – ident: e_1_3_5_23_2 doi: 10.1093/annonc/mdt136 – ident: e_1_3_5_32_2 doi: 10.1001/jamaoncol.2015.1341 – ident: e_1_3_5_40_2 doi: 10.1016/S1470-2045(17)30605-8 – ident: e_1_3_5_38_2 doi: 10.1002/pros.23182 – ident: e_1_3_5_28_2 doi: 10.1200/JCO.2007.12.4487 – reference: 32209284 - Eur Urol. 2020 Jun;77(6):758-759 – reference: 32212535 - N Engl J Med. 2020 Mar 26;382(13):1286 – reference: 31881143 - N Engl J Med. 2019 Dec 26;381(26):2564-2566 – reference: 31928459 - J Urol. 2020 Apr;203(4):662-663 – reference: 32029338 - Eur Urol. 2020 Apr;77(4):560-561 |
| SSID | ssj0000149 |
| Score | 2.7027354 |
| Snippet | A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that... The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic... BackgroundThe efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with... |
| SourceID | proquest pubmed crossref mms |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2506 |
| SubjectTerms | Aged Aged, 80 and over Analgesics Androgen Antagonists - administration & dosage Androgen Antagonists - adverse effects Androgens Androstenes - administration & dosage Androstenes - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Castration Colony-stimulating factor Death Granulocyte colony-stimulating factor Humans Infusions, Intravenous Kaplan-Meier Estimate Leukocytes (granulocytic) Male Metastases Metastasis Middle Aged Pain Patients Phenylthiohydantoin - administration & dosage Phenylthiohydantoin - adverse effects Phenylthiohydantoin - analogs & derivatives Prednisone Prednisone - administration & dosage Progression-Free Survival Prostate cancer Prostate-specific antigen Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Safety Survival Taxoids - administration & dosage Taxoids - adverse effects Working groups |
| Title | Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa1911206 https://www.ncbi.nlm.nih.gov/pubmed/31566937 https://www.proquest.com/docview/2330624583 https://www.proquest.com/docview/2299457633 |
| Volume | 381 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwEA_qQHwRv50fI4L4ZHFNs3R7Eh2TIU5EJuytJOkVJms79wGyv967LpvzYb6UQo8Scpfk98sl92PsGvGa0r5FbpJY5UlfGs8YheNKJxqqvolFITbReVXtD_ncq_XchtvYHatczInFRB3nlvbI7wQSbyUoy3c__PJINYqyq05CY5OVqHQZRXXYC1fKRzn463aQXI1NXPPvSGk-10hWfEFiRytr0maajtfDzWLZedpjuw4v8oe5g_fZBmQHbLvjMuKH7KWpjZ4hwf-GAacjFtMxfzCUPIdRngHPR7yVzTTGl077MfB-xjsw0XSPqG_5G935QFPeJOePjlj3qdVttj2nkOBZBD4TL65p27AgjJQQWJ3U64BwL0gawiLNMVQOMMAXsEkoE2ReVWVi7Yu4gU0LTDU4ZlsZtuWUcRmbUCHX8ENQEkLA74lQjViRuJX2VZndLroosq56OIlYDKIii11T0Z8eLbObpflwXjZjnWEF-zvK4DNdZ3CxcEXkhtc4-g2GMrtafsaBQdkOnUE-RRtcaCWyqQBtTuYuXDYlINaKwOzs_5-fsx3ER4VchFAXbGsymsIlYpCJqRSBhs9606-w0mPr9e39B12F2R8 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1NTxsxEB1BKhUuiFIo4auuVHpiRdbrOMkBIZSCAiSIQypxW9neWSkV2YVkIz7-E_-Rmc1uoIf0xm0ljyzLHtvv7XjmAfwkvKaN74ibxE57ylfWs1bTvjKxwZpvI5mLTfSudOePurip3yzAS5kLw88qyzMxP6ij1PE_8kNJxFtLjvId3917rBrF0dVSQmPqFpf49ECUbXx0_pvWd1_Ks9N-u-MVqgKeI7CQeVHduJZDaZXCwJm42USCSEHcko6ogeUSegF9oIsbKia2UtM2Mr6MWsaawNYC6nYRPqmAdiYnprf9d9WqCrRd_LAqSnoSxDhkYfvUEDfyJWsrvbsCF4fD8Xx0m99yZ6uwUsBTcTL1py-wgMkafO4VAfiv0G3T-J4HmXnEW8EvOiZjcWI5Vo-jNEGRjsRp8mzInc1wEKEYJKKHmeG0pYET15xiQqaizb42Wof-R0zdBlQSGssmCBXZhiZq4zdQK2wgtcdStyLNWlrG11U4KKcodEWxctbMuA3zoHldh__MaBV-zczvplU65hnu0XyHCf4dzjPYKZciLHbzOHzzvSr8mDXTPuTgikkwnZAN3euKyFtANt-mSzgbSsAkmXDg1v87_w5LnX6vG3bPry63YZmgWa5UIfUOVLLRBHcJ_mR2L3c6AeEHO_krKI8TbA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LTxsxEB4BlVAvCOgrPF2p7amrZL2ONzlUFQpEUAjiQCVuK9s7K6Uiu5BsxOOf8e-Y2XhTekhv3FbyyLLsGfv7duz5AL4QXtMmdMRNMqcDFSobWKsprkxmsBXaVFZiE4Nzffxb_bpqXy3BU_0Whq9V1ntitVGnheN_5E1JxFtLzvI1M38t4uKw__PmNmAFKc601nIaMxc5xYc7om-THyeHtNZfpewfXfaOA68wEDgCDmWQto3rOpRWKYycyTodJLgUZV3piCZYLqcX0Qe6LFYZMZeWtqkJZdo11kS2FVG3y_AmjuIOh1inF76oXOWRt_955ct7Etxossh9YYgnhZJ1ll4ch8uj0WQx0q1OvP46rHmoKg5mvrUBS5hvwurAJ-PfwVmPxvc4LM09Xgu-3TGdiAPLeXscFzmKYiyO8kdDrm1GwxTFMBcDLA0_YRo6ccHPTchU9Njvxu_h8jWm7gOs5DSWTyBUamNNNCeMUSuMkdozqbupZl0tE-oGfK-nKHG-cDnrZ1wnVQK9rZN_ZrQB3-bmN7OKHYsM92i-kxz_jBYZ7NRLkfjIniR__bABn-fNFJOcaDE5FlOyoTNeEZGLyObjbAnnQ4mYMBMm3Pp_5_uwSu6dnJ2cn27DW0JplWiF1DuwUo6nuEtIqLR7lc8JSF7Zx58B-8cXog |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cabazitaxel+versus+Abiraterone+or+Enzalutamide+in+Metastatic+Prostate+Cancer&rft.jtitle=The+New+England+journal+of+medicine&rft.au=de+Wit%2C+Ronald&rft.au=de+Bono%2C+Johann&rft.au=Sternberg%2C+Cora+N&rft.au=Fizazi%2C+Karim&rft.date=2019-12-26&rft.issn=1533-4406&rft.eissn=1533-4406&rft.volume=381&rft.issue=26&rft.spage=2506&rft_id=info:doi/10.1056%2FNEJMoa1911206&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |